Nantahala Capital Management LLC acquired a new stake in Apyx Medical Corporation (NASDAQ:APYX - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,270,248 shares of the company's stock, valued at approximately $14,683,414. Nantahala Capital Management LLC owned approximately 7.76% of Apyx Medical as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the stock. Nwam LLC purchased a new stake in Apyx Medical during the 1st quarter worth about $47,000. Citadel Advisors LLC purchased a new position in Apyx Medical in the 3rd quarter valued at about $28,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Apyx Medical in the 2nd quarter valued at about $62,000. Hudson Bay Capital Management LP acquired a new stake in shares of Apyx Medical during the 4th quarter worth about $73,000. Finally, Osaic Holdings Inc. acquired a new stake in shares of Apyx Medical during the 2nd quarter worth about $50,000. Institutional investors and hedge funds own 55.33% of the company's stock.
Apyx Medical Stock Performance
Shares of APYX stock opened at $3.08 on Friday. The company's fifty day simple moving average is $3.87 and its 200-day simple moving average is $3.84. The company has a current ratio of 5.68, a quick ratio of 4.53 and a debt-to-equity ratio of 3.19. Apyx Medical Corporation has a 52 week low of $1.70 and a 52 week high of $5.08. The company has a market cap of $129.73 million, a PE ratio of -15.40 and a beta of 1.39.
Apyx Medical (NASDAQ:APYX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.01. The firm had revenue of $13.88 million for the quarter, compared to the consensus estimate of $13.18 million. Apyx Medical had a negative net margin of 14.78% and a negative return on equity of 76.60%. As a group, equities research analysts anticipate that Apyx Medical Corporation will post -0.25 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Apyx Medical in a research report on Wednesday, June 24th. HC Wainwright assumed coverage on shares of Apyx Medical in a research report on Monday, July 13th. They set a "buy" rating and a $7.00 target price on the stock. Finally, Zacks Research raised shares of Apyx Medical to a "hold" rating in a research note on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $6.60.
Check Out Our Latest Stock Analysis on APYX
About Apyx Medical
(
Free Report)
Apyx Medical NASDAQ: APYX is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company's product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.
Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Apyx Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apyx Medical wasn't on the list.
While Apyx Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
